Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding
|Event Date/Time: Apr 11, 2010||End Date/Time: Apr 13, 2010|
Please submit all abstracts via email to Rachel Minnick, Program Developer Rachel.Minnick@diahome.org
All abstracts must be received by February 13, 2010
Authors of selected abstracts will be notified by March 13, 2010
Suggested Abstract Topics
(The strongest abstracts have been those with a clear hypothesis and supporting data with a strong scientific design)
Drug Development and CV safety
Â· Drug-induced increases in CV events
Â· Myocardial toxicity
Â· Pharmacogenomics and drug-induced CV injury
Â· How can we practically assess the negative inotropic potential of new drugs?
Â· Anticoagulant safetyâ€”how to measure it?
Evolving Science of QT/Arrhythmia Assessment